Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies.
Nanoscale
; 14(4): 1054-1074, 2022 Jan 27.
Article
in English
| MEDLINE | ID: covidwho-1621288
ABSTRACT
COVID-19 has caused a global pandemic and millions of deaths. It is imperative to develop effective countermeasures against the causative viral agent, SARS-CoV-2 and its many variants. Vaccines and therapeutic antibodies are the most effective approaches for preventing and treating COVID-19, respectively. SARS-CoV-2 enters host cells through the activities of the virus-surface spike (S) protein. Accordingly, the S protein is a prime target for vaccines and therapeutic antibodies. Dealing with particles with dimensions on the scale of nanometers, nanotechnology has emerged as a critical tool for rapidly designing and developing safe, effective, and urgently needed vaccines and therapeutics to control the COVID-19 pandemic. For example, nanotechnology was key to the fast-track approval of two mRNA vaccines for their wide use in human populations. In this review article, we first explore the roles of nanotechnology in battling COVID-19, including protein nanoparticles (for presentation of protein vaccines), lipid nanoparticles (for formulation with mRNAs), and nanobodies (as unique therapeutic antibodies). We then summarize the currently available COVID-19 vaccines and therapeutics based on nanotechnology.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
COVID-19
/
Antibodies
Topics:
Vaccines
/
Variants
Limits:
Humans
Language:
English
Journal:
Nanoscale
Year:
2022
Document Type:
Article
Affiliation country:
D1nr03831a
Similar
MEDLINE
...
LILACS
LIS